MIR-330-Mediated regulation of SH3GL2 expression enhances malignant behaviors of glioblastoma stem cells by activating ERK and PI3K/AKT signaling pathways

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Yao, Yilong ^a   Xue, Yixue ^a   Ma, Jun ^a   Shang, Chao ^a   Wang, Ping ^a   Liu, Libo ^a   Liu, Wenjing ^a   Li, Zhen ^a   Qu, Shengtao ^a   Li, Zhiqing ^a   Liu, Yunhui ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MIRN330 MICRORNA, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SH3GL2 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANIMAL; APOPTOSIS; CANCER STEM CELL; CELL MOTION; CELL PROLIFERATION; DISEASE MODEL; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; GLIOBLASTOMA; HUMAN; METABOLISM; MORTALITY; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; HUMANS; MICE; MICRORNAS; NEOPLASTIC STEM CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922391490     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095060     Document Type: Article

References (55)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
2. Ji J, Black KL, Yu JS (2010) Glioma stem cell research for the development of immunotherapy. Neurosurg Clin N Am 21: 159-166.
3. Fukaya R, Ohta S, Yamaguchi M, Fujii H, Kawakami Y, et al. (2010) Isolation of cancer stem-like cells from a side population of a human glioblastoma cell line, SK-MG-1. Cancer Lett 291: 150-157.
4. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, et al. (2009) Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4: 568-580.
5. Garzon R, Calin GA, Croce CM (2009) MicroRNAs in Cancer. Annu Rev Med 60: 167-179.
6. Nimmo RA, Slack FJ (2009) An elegant miRror: microRNAs in stem cells, developmental timing and cancer. Chromosoma 118: 405-418.
7. Yu X, Song H, Xia T, Han S, Xiao B, et al. (2013) Growth inhibitory effects of three miR-129 family members on gastric cancer. Gene.
8. Callegari E, Elamin BK, Sabbioni S, Gramantieri L, Negrini M (2013) Role of microRNAs in hepatocellular carcinoma: A clinical perspective. Onco Targets Ther 6: 1167-1178.
9. Koshkin PA, Chistiakov DA, Chekhonin VP (2013) Role of microRNAs in mechanisms of glioblastoma resistance to radio- And chemotherapy. Biochemistry (Mosc) 78: 325-334.
10. Palumbo S, Miracco C, Pirtoli L, Comincini S (2013) Emerging roles of microRNA in modulating cell-death processes in malignant glioma. J Cell Physiol.
11. Weber MJ (2005) New human and mouse microRNA genes found by homology search. FEBS J 272: 59-73.
12. Lee KH, Chen YL, Yeh SD, Hsiao M, Lin JT, et al. (2009) MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene 28: 3360-3370.
13. Pang Y, Young CY, Yuan H (2010) MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai) 42: 363-369.
14. Hodzic J, Giovannetti E, Diosdado B, Adema AD, Peters GJ (2011) Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells. Nucleosides Nucleotides Nucleic Acids 30: 1214-1222.
15. Giachino C, Lantelme E, Lanzetti L, Saccone S, Bella Valle G, et al. (1997) A novel SH3-containing human gene family preferentially expressed in the central nervous system. Genomics 41: 427-434.
16. Ringstad N, Nemoto Y, De Camilli P (1997) The SH3p4/Sh3p8/SH3p13 protein family: binding partners for synaptojanin and dynamin via a Grb2-like Src homology 3 domain. Proc Natl Acad Sci U S A 94: 8569-8574.
17. Dasgupta S, Jang JS, Shao C, Mukhopadhyay ND, Sokhi UK, et al. (2013) SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling. J Mol Med (Berl) 91: 381-393.
18. Shang C, Guo Y, Fu S, Fu W, Sun K (2010) SH3GL2 gene participates in MEK-ERK signal pathway partly by regulating EGFR in the laryngeal carcinoma cell line Hep2. Med Sci Monit 16: BR168-173.
19. Potter N, Karakoula A, Phipps KP, Harkness W, Hayward R, et al. (2008) Genomic deletions correlate with underexpression of novel candidate genes at six loci in pediatric pilocytic astrocytoma. Neoplasia 10: 757-772.
20. Soubeyran P, Kowanetz K, Szymkiewicz I, Langdon WY, Dikic I (2002) Cbl- CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature 416: 183-187.
21. Johnson H, Del Rosario AM, Bryson BD, Schroeder MA, Sarkaria JN, et al. (2012) Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts. Mol Cell Proteomics 11: 1724-1740.
22. Wang SC, Hung MC (2009) Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res 15: 6484-6489.
23. Mangelberger D, Kern D, Loipetzberger A, Eberl M, Aberger F (2012) Cooperative Hedgehog-EGFR signaling. Front Biosci (Landmark Ed) 17: 90-99.
24. Brand TM, Iida M, Wheeler DL (2011) Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther 11: 777-792.
25. Taylor TE, Furnari FB, Cavenee WK (2012) Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets 12: 197-209.
26. Hong Y, Sang M, Shang C, Xue YX, Liu YH (2012) Quantitative analysis of topoisomerase II alpha and evaluation of its effects on cell proliferation and apoptosis in glioblastoma cancer stem cells. Neurosci Lett 518: 138-143.
27. Zhang FL, Wang P, Liu YH, Liu LB, Liu XB, et al. (2013) Topoisomerase I inhibitors, shikonin and topotecan, inhibit growth and induce apoptosis of glioma cells and glioma stem cells. PLoS One 8: e81815.
28. Stiles CD, Rowitch DH (2008) Glioma stem cells: A midterm exam. Neuron 58: 832-846.
29. Qu S, Yao Y, Shang C, Xue Y, Ma J, et al. (2012) MicroRNA-330 is an oncogenic factor in glioblastoma cells by regulating SH3GL2 gene. PLoS One 7: e46010.
30. Li Y, Zhu X, Xu W, Wang D, Yan J (2013) miR-330 regulates the proliferation of colorectal cancer cells by targeting Cdc42. Biochem Biophys Res Commun 431: 560-565.
31. Mao Y, Chen H, Lin Y, Xu X, Hu Z, et al. (2013) microRNA-330 inhibits cell motility by downregulating Sp1 in prostate cancer cells. Oncol Rep 30: 327-333.
32. Zheng ZM, Wang X (2011) Regulation of cellular miRNA expression by human papillomaviruses. Biochim Biophys Acta 1809: 668-677.
33. Sinha S, Chunder N, Mukherjee N, Alam N, Roy A, et al. (2008) Frequent deletion and methylation in SH3GL2 and CDKN2A loci are associated with early- And late-onset breast carcinoma. Ann Surg Oncol 15: 1070-1080.
34. Majumdar S, Gong EM, Di Vizio D, Dreyfuss J, Degraff DJ, et al. (2013) Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior. Neoplasia 15: 749-760.
35. Maiti GP, Mondal P, Mukherjee N, Ghosh A, Ghosh S, et al. (2013) Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes. PLoS One 8: e63440.
36. de Moor CH, Meijer H, Lissenden S (2005) Mechanisms of translational control by the 39 UTR in development and differentiation. Semin Cell Dev Biol 16: 49- 58.
37. Robins H, Press WH (2005) Human microRNAs target a functionally distinct population of genes with AT-rich 39 UTRs. Proc Natl Acad Sci U S A 102: 15557-15562.
38. Henson ES, Gibson SB (2006) Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal 18: 2089-2097.
39. Kirisits A, Pils D, Krainer M (2007) Epidermal growth factor receptor degradation: An alternative view of oncogenic pathways. Int J Biochem Cell Biol 39: 2173-2182.
40. Dhillon AS, Hagan S, Rath O, Kolch W (2007) MAP kinase signalling pathways in cancer. Oncogene 26: 3279-3290.
41. Dudu V, Able RA Jr, Rotari V, Kong Q, Vazquez M (2012) Role of Epidermal Growth Factor-Triggered PI3K/Akt Signaling in the Migration of Medulloblastoma- Derived Cells. Cell Mol Bioeng 5: 502-413.
42. Chen J (2012) Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications. World J Virol 1: 154-161.
43. Ramjaun AR, Angers A, Legendre-Guillemin V, Tong XK, McPherson PS (2001) Endophilin regulates JNK activation through its interaction with the germinal center kinase-like kinase. J Biol Chem 276: 28913-28919.
44. Lin A, Dibling B (2002) The true face of JNK activation in apoptosis. Aging Cell 1: 112-116.
45. Vucic D, Dixit VM, Wertz IE (2011) Ubiquitylation in apoptosis: A posttranslational modification at the edge of life and death. Nat Rev Mol Cell Biol 12: 439-452.
46. Lin H, Chen C, Li X, Chen BD (2002) Activation of the MEK/MAPK pathway is involved in bryostatin1-induced monocytic differenciation and up-regulation of X-linked inhibitor of apoptosis protein. Exp Cell Res 272: 192-198.
47. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, et al. (2001) Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 276: 10767-10774.
48. Gibson EM, Henson ES, Haney N, Villanueva J, Gibson SB (2002) Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release. Cancer Res 62: 488-496.
49. Henson ES, Gibson EM, Villanueva J, Bristow NA, Haney N, et al. (2003) Increased expression of Mcl-1 is responsible for the blockage of TRAIL-induced apoptosis mediated by EGF/ErbB1 signaling pathway. J Cell Biochem 89: 1177-1192.
50. Johnstone RW, Frew AJ, Smyth MJ (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8: 782-798.
51. Salvesen GS, Duckett CS (2002) IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3: 401-410.
52. Fulda S (2009) Cell death in hematological tumors. Apoptosis 14: 409-423.
53. Jun T, Gjoerup O, Roberts TM (1999) Tangled webs: evidence of cross-talk between c-Raf-1 and Akt. Sci STKE 1999: PE1.
54. Aksamitiene E, Kiyatkin A, Kholodenko BN (2012) Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: A fine balance. Biochem Soc Trans 40: 139-146.
55. Chandarlapaty S (2012) Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov 2: 311-319.